SMED Clinical Research joins the Barcelona & Madrid Health Hub
Home News SMED Clinical Research joins the Barcelona & Madrid Health Hub

SMED Clinical Research joins the Barcelona & Madrid Health Hub

NOVEMBER 20, 2026 Members' News

Joining Barcelona & Madrid Health Hub marks an important step for SMED Clinical Research as the company continues to strengthen its presence within the healthcare and life sciences ecosystem. It creates new opportunities to stay close to innovation, collaborate with leading organisations, and better understand the evolving needs of sponsors, clinical sites and the patients they serve.

 

Why Does Clinical Evidence Matter?

Innovation in health only creates value when it reaches patients. Behind every approved therapy, diagnostic or digital health solution there is a long chain of scientific and regulatory decisions that must all be right: a well-designed protocol, feasible and well-selected sites, reliable data, rigorous statistics and full regulatory compliance.

When one of those links is weak, the consequences are serious. Studies are delayed or fail to recruit, data are questioned, promising assets lose years of development and investment is wasted. In the most critical cases, patients are exposed to unnecessary risk, and products that could have helped them never reach the market.

These risks are greatest in the areas where science moves fastest: oncology, immunology, advanced therapies and AI-driven innovation. In these fields, the difference between success and failure is usually decided long before the first patient is enrolled.

 

How Can SMED Clinical Research Help?

SMED Clinical Research is a full-service CRO and medical advisory company founded in February 2024 by Dr. Sonia Maciá, MD, PhD, MBA, a medical oncologist with more than 20 years of experience in clinical research. Our philosophy is simple: we are not just advisors, we are partners. We turn impossible into possible.

We combine clinical development with real-world clinical practice, and we work hand in hand with sponsors and clinical sites to deliver efficient, high-quality trials. We apply critical thinking and advanced machine-learning-driven biomarker and genomic signatures to optimise drug modelling and maximise the probability of success in developing innovative therapies.

 

What we offer:

  • Strategic medical advisory — protocol development, pathway planning with regulatory considerations, customised site recommendations with patient-estimation metrics and feasibility assessment integrated with clinical practice.
  • Clinical operations and regulatory — operational strategy, start-up, oversight and full regulatory support, tailored to each programme.
  • Medical monitoring and medical support — data analysis and interpretation, medical data review, safety oversight, and leadership of Data Safety Monitoring Board meetings, investigator meetings and advisory boards.
  • Medical writing — protocols, clinical study reports, patient informed consent forms, manuscripts and all protocol-related documents for regulatory submissions.
  • Biostatistics and data management — study design and statistical analysis, including adaptive and Bayesian designs, sample-size calculation and analysis of censored data.
  • Data science and AI — biomarker and genomic signature development, explainable machine learning models and in silico drug design.
  • Financial and market analysis — medical-perspective reports tailored by indication or study status, combined with market analysis and financial modelling for investors.

Therapeutic and functional expertise:

  • Oncology — extensive experience across all solid tumours
  • Immuno-oncology, cancer immunotherapy and advanced therapies (ATMPs)
  • Medical devices
  • Neurology, endocrinology, internal medicine, rheumatology and haematology
  • Clinical development, data management, biostatistics, regulatory and strategic advice, site selection and medical monitoring

Where we work:

  • All phases, from first-in-human Phase I studies to registration and post-authorisation
  • Global reach across Europe, Israel, USA, APAC and Latin America
  • Sponsor-side and site-side perspective

 

Proven Experience in Clinical Development

Our team has been involved in pivotal trials that ended in FDA approval, and has supported sponsors at every stage of the clinical development continuum.

SMED Clinical Research is registered as an SME with the European Medicines Agency (EMA) and takes part in the ACTEU (Accelerating Clinical Trials in the EU) initiative, and is a member of AseBio, the Spanish Bioindustry Association.

Our data science team develops models designed to be defensible rather than black boxes. The MET-score, an explainable machine learning model that continuously estimates metastatic risk in prostate cancer from transcriptomic data, was presented at ASCO and at the GUARD Consortium. We have also designed a new anti-DLL3 therapeutic candidate entirely in silico, without a single wet-lab experiment, for small cell lung cancer and other neuroendocrine tumours.

Our medical and operational teams have also represented our partners at ASCO, ESMO, ESMO MAP, ASCO GU, NextGen Biomed London and the Clinical Research Innovation Forum.

Through SMED Academy we train clinical research professionals, with modules on clinical operations, clinical research and regulatory affairs, and dedicated programmes on ATMPs, immuno-oncology and medical devices.

Accelerating Innovation:

From first-in-human studies to registration, and from biomarker signatures to regulatory submissions, clinical development should never be left to chance. A proactive, science-driven strategy helps protect patients, de-risk investment and bring better solutions to the people who need them.

We are delighted to become part of Barcelona & Madrid Health Hub and to contribute our clinical research expertise to its ecosystem of digital health innovators, healthcare organisations and investors.

 

For any enquiries, please feel free to contact us:

info@smedcr.com · +34 606 432 153 · www.smedcr.com

November 20, 2026 Members' News
Derm2check Breaks Away From One-Sided AI Skin Apps
Dutch platform combines a free AI skin check with an international network of dermatologists, from first suspicion to treatment Derm2check is the result of a pilot phase of about a year, during which broad experience was built up worldwide in digital dermatological care. That practical experience has now been incorporated into a fully renewed platform, which combines AI technology with a free AI Check for users.
Read more
November 20, 2026 Members' News
SMED Clinical Research joins the Barcelona & Madrid Health Hub
Joining Barcelona & Madrid Health Hub marks an important step for SMED Clinical Research as the company continues to strengthen its presence within the healthcare and life sciences ecosystem. It creates new opportunities to stay close to innovation, collaborate with leading organisations, and better understand the evolving needs of sponsors, clinical sites and the patients they serve.
Read more
November 19, 2026 Members' News
Partner Insights 2026: Technology, Innovation and Collaboration in Life Sciences
Ambit Iberia has launched Partner Insights 2026, the new edition of its annual magazine bringing together the perspectives of 13 technology partners on the trends, challenges and opportunities shaping the future of the Life Sciences industry.
Read more
November 19, 2026 Members' News
Artificial Intelligence comes to informed consent to answer patients’ questions before surgery
Informed consent is a routine process in any hospital, but its management continues to generate costs, administrative workload and traceability issues when carried out on paper. To address these challenges, ASHO has developed a new end-to-end informed consent management platform that digitizes the entire process and gives patients a more active role, allowing them to access the information in advance, resolve their questions before signing and arrive at surgery with a better understanding of the procedure.
Read more
November 18, 2026 Members' News
Corporate Nutrition for Every Type of Work. The Great Blind Spot in Workplace Wellness
Do we really take care of all the factors that influence team well-being? In recent years, companies have made progress in mental health, work-life balance, flexibility, and creating healthier work environments. However, there is one element that often remains outside the strategy or is treated in a merely informative way: nutrition during the workday.
Read more
November 16, 2026 Members' News
M2H brings exercise prescription into Primary Care: doctors and exercise specialists, finally on a single digital layer
The Barcelona-based healthtech startup, a new member of Barcelona & Madrid Health Hub, connects family doctors and Physical Exercise Specialists within the same clinical workflow, keeping full patient traceability.
Read more
November 13, 2026 Members' News
Fund It, Build It, Certify It: A MedTech Startup's Roadmap to Market
Most MedTech startups don't stall because the technology fails. They stall because funding and regulation were planned separately. Under MDR, compliance is not the last step before submission. It shapes your product and company decisions from day one. And investors know it: before a Series A or B, they expect a credible regulatory strategy, not just a promising prototype. That's why, QbD Group and Capital Cell teamed up, to bring both sides together in one free webinar live session.
Read more
November 13, 2026 Members' News
The Ultimate Guide for Choosing an Enterprise CMS
In strictly regulated industries like pharmaceutical and health insurance, delivering seamless, compliant digital experiences—from patient portals to provider resources—is critical. Magnolia is a leading composable Digital Experience Platform (DXP) trusted by healthcare and global enterprise giants like Sanofi and Generali. By centralizing websites, portals, and apps into one intuitive, open platform, Magnolia's CMS empowers IT teams to build freely and marketing teams to launch faster—all while protecting brand integrity and compliance.
Read more
November 12, 2026 Members' News
Health Tech Enterprise launches half-price UK market entry offer for Barcelona & Madrid Health Hub members
Health Tech Enterprise introduces an exclusive UK Market Entry Pathfinder offer for Barcelona & Madrid Health Hub members, helping MedTech companies assess their readiness for UK expansion and receive an evidence-based market entry recommendation within 21 days, with preferential member pricing available until 31 December 2026.
Read more
November 12, 2026 Members' News
Your Next Innovation May Already Exist
Connecting business challenges with scientific knowledge
Read more